September 28, 2018
- Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 12, 2018
- Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
September 4, 2018
- Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
July 31, 2018
- Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
July 24, 2018
- Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
June 26, 2018
- Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
June 26, 2018
- Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 19, 2018
- Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
May 31, 2018
- Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
April 30, 2018
- Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
Displaying 1 - 10 of 35 results